

Olga Igoucheva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2305144/publications.pdf>

Version: 2024-02-01

27
papers

712
citations

471509

17
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	Tâ€cell activation and bacterial infection in skin wounds of recessive dystrophic epidermolysis bullosa patients. <i>Experimental Dermatology</i> , 2022, 31, 1431-1442.	2.9	3
2	Intracellular escape strategies of <i>Staphylococcus aureus</i> in persistent cutaneous infections. <i>Experimental Dermatology</i> , 2021, 30, 1428-1439.	2.9	29
3	Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa. <i>Experimental Dermatology</i> , 2021, 30, 1724-1733.	2.9	15
4	Aberrant recruitment of leukocytes defines poor wound healing in patients with recessive dystrophic epidermolysis bullosa. <i>Journal of Dermatological Science</i> , 2020, 100, 209-216.	1.9	9
5	Congenital muscular dystrophy-associated inflammatory chemokines provide axes for effective recruitment of therapeutic adult stem cell into muscles. <i>Stem Cell Research and Therapy</i> , 2020, 11, 463.	5.5	5
6	High concordance between clinical diagnosis of epidermolysis bullosa and immunofluorescence with a small, well-matched antibody panel. <i>Australasian Journal of Dermatology</i> , 2018, 59, 73-76.	0.7	1
7	Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1126-1134.	0.7	47
8	Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2298-2308.	0.7	27
9	Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 14428-14442.	1.8	27
10	Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa. <i>Stem Cell Research and Therapy</i> , 2016, 7, 124.	5.5	8
11	Highly branched poly(β -amino ester)s for skin gene therapy. <i>Journal of Controlled Release</i> , 2016, 244, 336-346.	9.9	95
12	Fibulin-4 E57K Knock-in Mice Recapitulate Cutaneous, Vascular and Skeletal Defects of Recessive Cutis Laxa 1B with both Elastic Fiber and Collagen Fibril Abnormalities. <i>Journal of Biological Chemistry</i> , 2015, 290, 21443-21459.	3.4	42
13	Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy. <i>Stem Cell Research and Therapy</i> , 2014, 5, 21.	5.5	45
14	Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues. <i>Cytotherapy</i> , 2013, 15, 171-184.e1.	0.7	29
15	Chemokine-enhanced DNA vaccination in cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e26092.	4.6	3
16	Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder. <i>Cytotherapy</i> , 2011, 13, 30-45.	0.7	31
17	Protein Therapeutics for Junctional Epidermolysis Bullosa: Incorporation of Recombinant β 3 Chain into Laminin 332 in β 3 ^{-/-} Keratinocytes In Vitro. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1476-1486.	0.7	25
18	Oligonucleotide-Mediated Gene Targeting in Human Hepatocytes: Implications of Mismatch Repair. <i>Oligonucleotides</i> , 2008, 18, 111-122.	2.7	18

#	ARTICLE	IF	CITATIONS
19	Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1755-1764.	4.1	44
20	Involvement of ERCC1/XPF and XPG in Oligodeoxynucleotide-directed Gene Modification. <i>Oligonucleotides</i> , 2006, 16, 94-104.	2.7	26
21	Gene Targeting by Oligonucleotides in Keratinocytes. , 2005, 289, 287-302.		2
22	Oligonucleotide-Directed Mutagenesis and Targeted Gene Correction: A Mechanistic Point of View. <i>Current Molecular Medicine</i> , 2004, 4, 445-463.	1.3	61
23	Mechanism of Gene Repair Open for Discussion. <i>Oligonucleotides</i> , 2004, 14, 311-321.	2.7	16
24	Transcription affects formation and processing of intermediates in oligonucleotide-mediated gene alteration. <i>Nucleic Acids Research</i> , 2003, 31, 2659-2670.	14.5	58
25	Biased gene repair needs unbiased review. <i>Nature Reviews Genetics</i> , 2003, 4, 752-752.	16.3	0
26	Expectations and reality in gene repair. <i>Nature Biotechnology</i> , 2002, 20, 1197-1198.	17.5	21
27	Targeted Single-Base Correction by RNA-DNA Oligonucleotides. <i>Human Gene Therapy</i> , 2000, 11, 2307-2312.	2.7	25